FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103257412> ?p ?o ?g. }

• W2103257412 endingPage "4608" @default.
• W2103257412 startingPage "4602" @default.
• W2103257412 abstract "Purpose To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and Methods Efficacy data from a large randomized phase III study of GC versus MVAC were updated. Time-to-event analyses were performed on the observed distributions of overall and progression-free survival. Results A total of 405 patients were randomly assigned: 203 to the GC arm and 202 to the MVAC arm. At the time of analysis, 347 patients had died (GC arm, 176 patients; MVAC arm, 171 patients). Overall survival was similar in both arms (hazard ratio [HR], 1.09; 95% CI, 0.88 to 1.34; P = .66) with a median survival of 14.0 months for GC and 15.2 months for MVAC. The 5-year overall survival rates were 13.0% and 15.3%, respectively (P = .53). The median progression-free survival was 7.7 months for GC and 8.3 months for MVAC, with an HR of 1.09. The 5-year progression-free survival rates were 9.8% and 11.3%, respectively (P = .63). Significant prognostic factors favoring overall survival included performance score (> 70), TNM staging (M0 v M1), low/normal alkaline phosphatase level, number of disease sites (≤ three), and the absence of visceral metastases. By adjusting for these prognostic factors, the HR was 0.99 for overall survival and 1.01 for progression-free survival. The 5-year overall survival rates for patients with and without visceral metastases were 6.8% and 20.9%, respectively. Conclusion Long-term overall and progression-free survival after treatment with GC or MVAC are similar. These results strengthen the role of GC as a standard of care in patients with locally advanced or metastatic TCC." @default.
• W2103257412 created "2016-06-24" @default.
• W2103257412 creator A5003643368 @default.
• W2103257412 creator A5007280131 @default.
• W2103257412 creator A5023611167 @default.
• W2103257412 creator A5028534654 @default.
• W2103257412 creator A5040028722 @default.
• W2103257412 creator A5052268554 @default.
• W2103257412 creator A5056035743 @default.
• W2103257412 creator A5077674568 @default.
• W2103257412 creator A5081315096 @default.
• W2103257412 date "2005-07-20" @default.
• W2103257412 modified "2023-10-14" @default.
• W2103257412 title "Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer" @default.
• W2103257412 cites W1820014750 @default.
• W2103257412 cites W1855374361 @default.
• W2103257412 cites W1857682357 @default.
• W2103257412 cites W1867318780 @default.
• W2103257412 cites W1893740135 @default.
• W2103257412 cites W1968487988 @default.
• W2103257412 cites W1972705109 @default.
• W2103257412 cites W2000366267 @default.
• W2103257412 cites W2000416122 @default.
• W2103257412 cites W2014400851 @default.
• W2103257412 cites W2024564253 @default.
• W2103257412 cites W2101562875 @default.
• W2103257412 cites W2122937444 @default.
• W2103257412 cites W2151796645 @default.
• W2103257412 cites W2165427711 @default.
• W2103257412 cites W2168812605 @default.
• W2103257412 doi "https://doi.org/10.1200/jco.2005.07.757" @default.
• W2103257412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16034041" @default.
• W2103257412 hasPublicationYear "2005" @default.
• W2103257412 type Work @default.
• W2103257412 sameAs 2103257412 @default.
• W2103257412 citedByCount "1504" @default.
• W2103257412 countsByYear W21032574122012 @default.
• W2103257412 countsByYear W21032574122013 @default.
• W2103257412 countsByYear W21032574122014 @default.
• W2103257412 countsByYear W21032574122015 @default.
• W2103257412 countsByYear W21032574122016 @default.
• W2103257412 countsByYear W21032574122017 @default.
• W2103257412 countsByYear W21032574122018 @default.
• W2103257412 countsByYear W21032574122019 @default.
• W2103257412 countsByYear W21032574122020 @default.
• W2103257412 countsByYear W21032574122021 @default.
• W2103257412 countsByYear W21032574122022 @default.
• W2103257412 countsByYear W21032574122023 @default.
• W2103257412 crossrefType "journal-article" @default.
• W2103257412 hasAuthorship W2103257412A5003643368 @default.
• W2103257412 hasAuthorship W2103257412A5007280131 @default.
• W2103257412 hasAuthorship W2103257412A5023611167 @default.
• W2103257412 hasAuthorship W2103257412A5028534654 @default.
• W2103257412 hasAuthorship W2103257412A5040028722 @default.
• W2103257412 hasAuthorship W2103257412A5052268554 @default.
• W2103257412 hasAuthorship W2103257412A5056035743 @default.
• W2103257412 hasAuthorship W2103257412A5077674568 @default.
• W2103257412 hasAuthorship W2103257412A5081315096 @default.
• W2103257412 hasConcept C121608353 @default.
• W2103257412 hasConcept C126322002 @default.
• W2103257412 hasConcept C126894567 @default.
• W2103257412 hasConcept C143998085 @default.
• W2103257412 hasConcept C207103383 @default.
• W2103257412 hasConcept C2776694085 @default.
• W2103257412 hasConcept C2777132456 @default.
• W2103257412 hasConcept C2778065480 @default.
• W2103257412 hasConcept C2778239845 @default.
• W2103257412 hasConcept C2778397455 @default.
• W2103257412 hasConcept C2780258809 @default.
• W2103257412 hasConcept C2780352672 @default.
• W2103257412 hasConcept C2780739268 @default.
• W2103257412 hasConcept C2781059491 @default.
• W2103257412 hasConcept C2781303535 @default.
• W2103257412 hasConcept C44249647 @default.
• W2103257412 hasConcept C71924100 @default.
• W2103257412 hasConcept C90924648 @default.
• W2103257412 hasConceptScore W2103257412C121608353 @default.
• W2103257412 hasConceptScore W2103257412C126322002 @default.
• W2103257412 hasConceptScore W2103257412C126894567 @default.
• W2103257412 hasConceptScore W2103257412C143998085 @default.
• W2103257412 hasConceptScore W2103257412C207103383 @default.
• W2103257412 hasConceptScore W2103257412C2776694085 @default.
• W2103257412 hasConceptScore W2103257412C2777132456 @default.
• W2103257412 hasConceptScore W2103257412C2778065480 @default.
• W2103257412 hasConceptScore W2103257412C2778239845 @default.
• W2103257412 hasConceptScore W2103257412C2778397455 @default.
• W2103257412 hasConceptScore W2103257412C2780258809 @default.
• W2103257412 hasConceptScore W2103257412C2780352672 @default.
• W2103257412 hasConceptScore W2103257412C2780739268 @default.
• W2103257412 hasConceptScore W2103257412C2781059491 @default.
• W2103257412 hasConceptScore W2103257412C2781303535 @default.
• W2103257412 hasConceptScore W2103257412C44249647 @default.
• W2103257412 hasConceptScore W2103257412C71924100 @default.
• W2103257412 hasConceptScore W2103257412C90924648 @default.
• W2103257412 hasIssue "21" @default.
• W2103257412 hasLocation W21032574121 @default.
• W2103257412 hasLocation W21032574122 @default.
• W2103257412 hasOpenAccess W2103257412 @default.

• next